Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2023 May;58(5):478-490.
doi: 10.1038/s41409-023-01928-2. Epub 2023 Feb 27.

Cardiovascular events among recipients of hematopoietic stem cell transplantation-A systematic review and meta-analysis

N Aghel  1 , M Lui  2 , V Wang  3 , D Khalaf  4 , H Mian  5 , C Hillis  4 , I Walker  6 , B Leber  6 , J H Lipton  7 , M Aljama  5 , K Lepic  4 , T Berg  5 , A Garcia-Horton  5 , J Petropoulos  8 , H Masoom  6 , D P Leong  9
Affiliations
Meta-Analysis

Cardiovascular events among recipients of hematopoietic stem cell transplantation-A systematic review and meta-analysis

N Aghel et al. Bone Marrow Transplant. 2023 May.

Abstract

Cardiovascular diseases are an emerging cause of mortality and morbidity in survivors of hematopoietic stem cell transplantation (HSCT); however, the incidence of cardiovascular events (CVEs) in this population is not well described. This systematic review summarizes the evidence on the incidence of CVEs in HSCT recipients. Medline and Embase were searched from inception to December 2020. Inclusion criteria were cohort studies and phase 3 randomized controlled trials that reported CVEs among adults who underwent HSCT for hematological malignancies. After reviewing 8386 citations, 57 studies were included. The incidence of CVEs at 100 days was 0.19 (95% CI: 0.17-0.21) per 100 person-days after autologous HSCT and 0.06 (95% CI: 0.05-0.07) per 100 person-days after allogeneic HSCT. This higher incidence after autologous HSCT was driven by reports of arrhythmia from one population-based study in patients with multiple myeloma. The incidence of long-term CVEs was 3.98 (95% CI; 3.44-4.63) per 1000 person-years in survivors of autologous HSCT and 3.06 (95% CI; 2.69-3.48) per 1000 person-years in survivors of allogeneic HSCT. CVEs remain an important but under-reported cause of morbidity and mortality in recipients of HSCT. Future studies are required to better understand the incidence and risk factors for CVEs in HSCT recipients.

PubMed Disclaimer

References

    1. Majhail NS, Tao L, Bredeson C, Davies S, Dehn J, Gajewski JL, et al. Prevalence of hematopoietic cell transplant survivors in the United States. Biol Blood Marrow Transpl. 2013;19:1498–501. - DOI
    1. Chow EJ, Mueller BA, Baker KS, Cushing-Haugen KL, Flowers MED, Martin PJ, et al. Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation. Ann Intern Med. 2011;155:21–37. - PubMed - DOI
    1. Armenian SH, Chemaitilly W, Chen M, Chow EJ, Duncan CN, Jones LW, et al. National institutes of health hematopoietic cell transplantation late effects initiative: The cardiovascular disease and associated risk factors working group report. Biol Blood Marrow Transpl. 2017;23:201–10. - DOI
    1. Armenian SH, Sun CL, Mills G, Teh JB, Francisco L, Durand JB, et al. Predictors of Late Cardiovascular Complications in Survivors of Hematopoietic Cell Transplantation. Biol Blood Marrow Transpl. 2010;16:1138–44. - DOI
    1. Tichelli A, Rovó A, Passweg J, Schwarze CP, Van Lint MT, Arat M, et al. Late complications after hematopoietic stem cell transplantation. Vol. 2, Expert Review of Hematology. Taylor & Francis; 2009. p. 583–601.

MeSH terms

LinkOut - more resources